Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

‘World first’ treatment for Type 1 diabetes launched

The trial hopes to replace the need for Type 1 diabetes patients to use insulin injections (Cardiff and Vale University Health Board/PA)
The trial hopes to replace the need for Type 1 diabetes patients to use insulin injections (Cardiff and Vale University Health Board/PA)

A groundbreaking trial to prevent and manage Type 1 diabetes has been launched by a health board.

Doctors hope a new drug will help regrow lost insulin-producing cells in the bodies of patients suffering from the chronic disease.

The Clinical Research Facility at Cardiff and Vale University Health Board have now dosed two patients with the drug, who are the first in the world to be tested with it.

Patients suffering from Type 1 diabetes usually treat the lifelong condition with insulin injections, as their pancreas cannot naturally produce enough of the beta cells which create the hormone.

An injection
Insulin is administered to Type 1 patients by injection (David Cheskin/PA)

But the world first trial in Cardiff aims to regenerate the lost cells and allow their bodies to naturally regulate blood glucose levels.

The health board said the new drug has shown no major side-effects, but it is too early to see if the trial has been successful.

It now hopes to attract up to eight more adult volunteers who have had diabetes for more than two years to take part in the trial.

Dr Mohammad Alhadj Ali, who is working on the study in Cardiff, said: “Despite everything achieved in diabetes care, advances in prevention haven’t really occurred.

“More insulin-producing beta cells are needed for those with this form of diabetes and it is estimated that 90% of patients with Type 1 diabetes have less than five per cent of insulin making cells left.”